BiotechTube

Brodalumab + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Mar 7, 2017 → Sep 23, 2019

NCT ID
NCT02985983

About Brodalumab + Placebo

Brodalumab + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02985983. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (6) Terminated (1) Active (14)
🔄Ixekizumab + PlaceboEli LillyPhase 3
🔄Ixekizumab + PlaceboEli LillyPhase 3
🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
✅AdalimumabAbbVieApproved
🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
🔄adalimumab + PlaceboAbbViePhase 3
🔄GolimumabMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02985983Phase 3Completed

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
36
SHR-1314Jiangsu Hengrui MedicinePhase 1
29
UpadacitinibAbbViePre-clinical
33
AdalimumabAbbVieApproved
35
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
40
adalimumab + PlaceboAbbViePhase 3
40
TreatmentMerckPre-clinical
66
GolimumabMerckPhase 3
40
Tulisokibart + PlaceboMerckPhase 2
42
Secukinumab 150 milligram [Cosentyx]NovartisApproved
39
secukinumabNovartisPre-clinical
26
Secukinumab + PlaceboNovartisPhase 3
40
Secukinumab + Placebo + SecukinumabNovartisApproved
47
Secukinumab + Secukinumab and PlaceboNovartisPhase 3
40
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
40
Brodalumab 210 mg + PlaceboAmgenPhase 2
27
Etanercept 25mg + SulfasalazinePfizerPhase 2
31